An analysis questions if Hims & Hers Health, Inc. (HIMS) is a top weight loss stock following an increase in its target price by Barclays.

Hims & Hers Health stock experienced a significant crash. The article aims to explain the reasons behind this notable decrease in share value.

A series of financial articles provides analysis on whether various company stocks, including major players like Apple, Tesla, and Nvidia, represent good investment opportunities. These reports offer insights into potential buys in the current market.

Shares of Hims & Hers Health experienced a decline on April 21 after Amazon introduced a new competing weight loss program, impacting investor sentiment.

Shares of Hims & Hers Health Inc. surged following news that Robert F. Kennedy Jr. is seeking to ease regulations on peptides, a move that could benefit the telehealth company.

Several stocks, including Bumble, Hims & Hers Health, Blue Owl, and Netskope, are making significant moves in premarket trading, indicating potential volatility for the upcoming trading session.

Hims & Hers Health, Inc. has provided a summary of its earnings call for the fourth quarter of 2025.

Hims & Hers Health, Inc. (HIMS) has announced a 2026 revenue forecast that surpasses market estimates, indicating strong projected financial performance.

Hims & Hers Health is being assessed for its potential for sustained long-term growth in the market.

Multiple articles provide analysis on various stocks, including high-growth AI companies, Visa, SoundHound AI, Western Digital, DNOW, HEICO, Spotify, TransAlta, Applied Materials, CoreWeave, Honeywell, and Illinois Tool Works, evaluating their potential as investment opportunities.

Hims & Hers Health, Inc. has released its summary for the Q1 2026 earnings call.

Hims & Hers Health, Inc. stock saw a rise after J.P. Morgan initiated coverage with an Overweight rating, citing a rich catalyst path for the company.

Cedar Grove Capital Management reportedly profited from its short position in Hims & Hers Health, indicating a successful bearish bet on the telehealth company.

A new partnership with Novo is fueling long-term optimism for Hims & Hers Health, Inc. (HIMS), suggesting positive future growth prospects for the company.

An asset manager has divested its holdings in Hims & Hers Health, indicating a significant change in investment strategy for the healthcare company's stock.

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration  AP News

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

These are the stocks posting the largest moves in early trading.

Hims & Hers Health announced its latest financial results, with GAAP EPS of $0.08, surpassing estimates by $0.03, and revenue of $617.82M, which was in-line with expectations.

This article provides a summary of significant corporate deals and transactions that occurred this week, featuring companies such as Visa, Hims & Hers Health, and Salesforce.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

Several companies, including Onto Innovation, Hims & Hers Health, and Akamai, have announced or priced significant offerings of convertible senior notes. These financial moves aim to raise capital through debt instruments.

An analysis compares the revenue performance of GoodRx and Hims & Hers Health, highlighting stagnation in one company versus growth in the other.

The stock price of Hims & Hers Health, Inc. reacted strongly following a crucial review by the U.S. Food and Drug Administration. The market's response indicates the significance of the FDA's findings for the company's future.

Hims & Hers Health saw its stock jump following news of the FDA's review of compounded peptide therapies, indicating market reaction to potential regulatory developments in the wellness sector.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

Several stocks, including Hims & Hers Health, oil stocks, and Live Nation Entertainment, are making significant moves in premarket trading, with Hims & Hers specifically upgraded to Buy from Hold by Needham.

Barclays has lowered its price target on Hims & Hers Health, Inc. (HIMS) to $25 while keeping an Overweight rating.

After a 70% decline over the past year, questions arise about whether Hims & Hers Health stock can bounce back.